Nogo-A Regulates Myogenesis Via Interacting with Filamin-C
Total Page:16
File Type:pdf, Size:1020Kb
Park et al. Cell Death Discovery (2021) 7:1 https://doi.org/10.1038/s41420-020-00384-x Cell Death Discovery ARTICLE Open Access Nogo-A regulates myogenesis via interacting with Filamin-C SunYoung Park1,2,Ji-HwanPark3, Un-Beom Kang4, Seong-Kyoon Choi5,6,AhmedElfadl1,H.M.ArifUllah1, Myung-Jin Chung1, Ji-Yoon Son1,HyunHoYun1, Jae-Min Park1,Jae-hyukYim1,Seung-JunJung1,Sang-HyupKim1, Young-Chul Choi7, Dae-Seong Kim8, Jin-Hong Shin8, Jin-Sung Park9,KeunHur 10, Sang-Han Lee11,Eun-JooLee1, Daehee Hwang12 and Kyu-Shik Jeong 1,2 Abstract Among the three isoforms encoded by Rtn4, Nogo-A has been intensely investigated as a central nervous system inhibitor. Although Nogo-A expression is increased in muscles of patients with amyotrophic lateral sclerosis, its role in muscle homeostasis and regeneration is not well elucidated. In this study, we discovered a significant increase in Nogo-A expression in various muscle-related pathological conditions. Nogo−/− mice displayed dystrophic muscle structure, dysregulated muscle regeneration following injury, and altered gene expression involving lipid storage and muscle cell differentiation. We hypothesized that increased Nogo-A levels might regulate muscle regeneration. Differentiating myoblasts exhibited Nogo-A upregulation and silencing Nogo-A abrogated myoblast differentiation. Nogo-A interacted with filamin-C, suggesting a role for Nogo-A in cytoskeletal arrangement during myogenesis. In conclusion, Nogo-A maintains muscle homeostasis and integrity, and pathologically altered Nogo-A expression mediates muscle regeneration, suggesting Nogo-A as a novel target for the treatment of myopathies in clinical settings. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction during myogenesis, a multistep process including trans- Muscular dystrophies are a group of genetic muscle formation of satellite cells into myoblasts, differentiation disorders that cause defective muscle fiber function due to into fusion-competent myoblasts, and their fusion into the weakening and breakdown of muscle fibers as a result multinucleated myotubes5,6. Myogenesis is regulated by of inflammation accompanied with abrogated muscle the synchronized actions of the myogenic regulatory regeneration. Duchenne muscular dystrophy (DMD), the factors myogenic factor 5, MyoD, and myogenin, and most common form of muscular dystrophy, is severe results in the expression of muscle-specific genes7,8. myopathy associated with an abrogated dystrophin gene, During differentiation, the Pax3 and Pax7 expression which results in muscle membrane frailty associated with levels are downregulated, although satellite cells retain – increased pro-inflammatory cytokine levels, mitochon- Pax7 expression during quiescence9 11. – drial dysfunction, and impaired satellite cell polarity1 4. The neurite outgrowth inhibitor Nogo, also known as Following injury, satellite cells transform to committed reticulon 4, is encoded by Rtn4. Independently cloned by – myoblasts and ultimately differentiate into myofibers three groups12 14, Rtn4 complementary DNA (cDNA) was found to generate three Nogo isoforms, Nogo-A, Nogo-B, and Nogo-C, by alternative splicing or distinctive Correspondence: Kyu-Shik Jeong ([email protected]) 15,16 1Department of Pathology, College of Veterinary Medicine, Kyungpook promoter usage . Although mainly localized to the National University, Daegu 41566, Republic of Korea endoplasmic reticulum (ER), Nogo has also been observed 2 Stem Cell Therapeutic Research Institute, Kyungpook National University, on the cell surface17. Nogo-A, the largest Nogo isoform, Daegu 41566, Republic of Korea Full list of author information is available at the end of the article which also carries an inhibitor region named Δ20, is a Edited by Ivano Amelio © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a linktotheCreativeCommons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Official journal of the Cell Death Differentiation Association Park et al. Cell Death Discovery (2021) 7:1 Page 2 of 18 potent neurite growth inhibitor in the central nervous The expression levels of Nogo and myogenic factors are system (CNS)14,15. Nogo-A is expressed in the brain, altered in animal models of muscle disorders spinal cord, eye, and skeletal muscle18, and most of our The muscles of mdx mice, the animal model of human knowledge on Nogo-A concerns its function as a neurite DMD, showed significantly elevated mRNA levels of outgrowth inhibitor in the CNS13,19. On the surface of Nogo-A (Fig. 2A), MyoD, and myogenin (Fig. 2B), and a cells, Nogo-A acts via its receptors Nogo-66 receptor 1, reduced Nogo-C mRNA level (Fig. 2A) compared with the sphingosine-1-phosphate receptor (S1PR) 2, and myelin- wild-type (WT) mice. These results were consistent with associated glycoprotein. Nogo isoforms binds Nogo-66 our analyses in human muscle samples from myopathies receptor 1 and inhibits neurite growth via the Rho/Rho- (Fig. 1B). The observed upregulation in Nogo-A and associated kinase signaling pathway14,18,20,21. However, Myod transcript levels was accompanied by increases in the mechanisms underlying the role of Nogo-A in muscle their protein levels (Fig. 2C, D). Dasarathy et al.22 have regeneration and myogenesis in skeletal muscle remain demonstrated a relationship between skeletal muscle loss elusive. and alcoholic liver disease (ALD); thus, we also analyzed In the present study, we also elucidate the role of Nogo in the skeletal muscle in a mouse model of ALD as a myo- the regulation of muscle homeostasis, muscle differentia- pathy model associated with chronic liver dysfunction. In tion, and adipocyte differentiation based on the muscle current study, the mouse ALD model successfully exhib- + + − − transcriptome profiles of Nogo / and Nogo / mice. We ited liver pathology including hepatomegaly, determined − − use a muscle-injury model in Nogo / mice to examine by the ratio of liver weight to body weight (Fig. S1A), and Nogo-A involvement in muscle regeneration and further elevated levels of plasma aspartate aminotransferase demonstrate the potent myogenic function of Nogo-A in (AST) and alanine aminotransferase (ALT) (Fig. S1C) myoblast differentiation using muscle lineage cells, compared to the control mice. Therefore, the elevated including C2C12 cells and induced muscle stem cells plasma ALT and AST levels in ALD mice suggest liver (iMSCs). Our findings suggest that the expression of Nogo- dysfunction as well as muscle damage (Fig. S1C). The A is altered in the skeletal muscle during pathological skeletal muscle tissues of the ALD mice exhibited upre- processes, and that Nogo-A serves a critical function in gulated Nogo-A and reduced Nogo-C mRNA levels muscle regeneration and maintenance of muscle integrity. compared to the controls (Fig. 2E); the tissues also showed elevated levels of myogenin and Pax7 (Fig. 2F), + Results suggesting increased numbers of committed Pax7 Nogo expression is altered in the muscle tissue of patients satellite cells and myogenin-positive myoblasts. with myopathies Acute muscle injury induced by notexin injection was Muscle tissue samples from patients with different associated with a dramatic increase in Nogo-A and a myopathies, including DMD and inflammatory myopathy, significant reduction in Nogo-C (Fig. 2G), as well as sig- exhibited typical histopathological features of muscle nificant upregulation of Myod and myogenin (Fig. 2H). In + degeneration including damaged myofiber structure, these animals, the number of Pax7 committed satellite inflammatory cell infiltration, and fibrosis resulting from cells was not altered but the MYH2 expression was dra- incomplete muscle regeneration (Fig. 1A). Thus, we matically downregulated, indicating structural muscle examined the transcriptional expression levels of Nogo damage (Fig. 2H). isoforms and myogenic factors in muscle tissues from patients with myopathies including DMD and inflamma- Muscle lacking Nogo exhibits abnormal structure and tory myopathy, which revealed that the levels of Nogo impaired regeneration following notexin-induced muscle isoforms were significantly altered in the muscle samples injury + + of patients with myopathies (Fig. 1B). Specifically, Although the Nogo-A / muscles exhibited well- although the level of Nogo-B in myopathic tissues was structured muscle fibers and the absence of inflamma- − − comparable to that in normal muscle tissues, the level of tory cell infiltration, the Nogo / muscles displayed Nogo-A was dramatically elevated and the level of Nogo- defective myofibers and exhibited immune cell infiltration C was significantly reduced in the myopathic tissues (Fig. 3A, right panel, arrow). Notexin-induced muscle compared with the normal tissues (Fig. 1B). The tran- damage results in inflammation at the site of injection script levels of Pax7,